Customising therapy in femoropopliteal revascularisation

137

Gary Ansel (Columbus, USA) tells Vascular News at VEITHSymposium 2018 about how drug-based therapies have become a mainstay in femoropopliteal revascularisation and how interventionalists should be using best medical therapy “more than we do [currently]”. He also shares his approach to making the choice between using a drug-coated balloon and a drug-eluting stent.

(Visited 31 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here